SGMT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

5.860

Open

5.650

VWAP

5.72

Vol

220.96K

Mkt Cap

187.32M

Low

5.540

Amount

1.26M

EV/EBITDA(TTM)

--

Total Shares

32.52M

EV

70.63M

EV/OCF(TTM)

--

P/S(TTM)

--

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Show More

Events Timeline

(ET)

2026-02-02

07:20:00

Ascletis Reports Positive Results for ASC40 Clinical Trial

2025-12-18 (ET)

2025-12-18

07:10:00

Sagimet Biosciences Reports Positive Results from Combination Drug Trial

2025-12-10 (ET)

2025-12-10

07:10:00

Sagimet Biosciences Grants Ascletis Pharma License for Acne Drug

2025-11-13 (ET)

2025-11-13

07:34:13

Sagimet Biosciences Announces Q3 Earnings Per Share of 40 Cents, Exceeding Consensus Estimate of 39 Cents

2025-11-10 (ET)

2025-11-10

07:54:55

Sagimet Biosciences Unveils Two Posters on Denifanstat at AASLD

News

Barron's

Sagimet Stock Increases Following Acne Treatment Success

seekingalpha

02-03seekingalpha

Guggenheim Initiates Buy on Sagimet Biosciences with Blockbuster Potential

seekingalpha

01-29seekingalpha

Sagimet Biosciences Shares Drop 9% Following Partner's Trial Data Release

PRnewswire

01-29PRnewswire

Ascletis' Denifanstat Receives Approval for Acne Treatment

Newsfilter

01-29Newsfilter

Ascletis' Denifanstat Receives Approval for Acne Treatment

Yahoo Finance

01-27Yahoo Finance

CancerVAX Appoints Dr. George Kemble as Senior Scientific Advisor

10 Analyst Rating

Wall Street analysts forecast SGMT stock price to rise

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

27.00

High

37.00

Current: 0.000

Low

8.00

Averages

27.00

High

37.00

Guggenheim

Seamus Fernandez

Buy

initiated

$27

AI Analysis

2026-02-03

Reason

Guggenheim

Seamus Fernandez

Price Target

$27

AI Analysis

2026-02-03

initiated

Buy

Reason

Guggenheim analyst Seamus Fernandez initiated coverage of Sagimet Biosciences with a Buy rating and $27 price target. The firm believes the company has "two distinct, underappreciated potential blockbuster opportunities" for its FASN inhibitor portfolio in advanced F4 MASH and moderate-to-severe acne, the analyst tells investors. In MASH, lead asset denifanstat's Phase 2b FASCINATE-2 data demonstrated competitive efficacy as an oral therapy, while in acne, partner Ascletis has validated denifanstat's efficacy across a Phase 2 and 3 study in China, the analyst noted.

Clear Street

NULL -> Buy

maintain

$29 -> $37

2026-02-03

Reason

Clear Street

Price Target

$29 -> $37

2026-02-03

maintain

NULL -> Buy

Reason

Clear Street raised the firm's price target on Sagimet Biosciences to $37 from $29 and keeps a Buy rating on the shares. The firm says the 52-week open-label Phase 3 safety update for denifanstat "was largely a clearing event." Although efficacy was not the primary focus, Sagimet noted sustained and progressive improvement over time in patients who remained on denifanstat beyond the initial 12 weeks, the analyst tells investors in a research note. Clear Street sees this as a validating long-term dataset with direct read-through to Sagimet's next-generation FASN inhibitor, TVB-3567.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGMT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Sagimet Biosciences Inc (SGMT.O) is -3.36, compared to its 5-year average forward P/E of -2.65. For a more detailed relative valuation and DCF analysis to assess Sagimet Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.65

Current PE

-3.36

Overvalued PE

-1.07

Undervalued PE

-4.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.21

Current EV/EBITDA

-0.85

Overvalued EV/EBITDA

0.48

Undervalued EV/EBITDA

-0.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

6.40

Current PS

0.00

Overvalued PS

38.72

Undervalued PS

-25.92

Financials

AI Analysis

Annual

Quarterly

Whales Holding SGMT

Affinity Asset Advisors, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Sagimet Biosciences Inc (SGMT) stock price today?

The current price of SGMT is 5.76 USD — it has increased 2.49

What is Sagimet Biosciences Inc (SGMT)'s business?

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

What is the price predicton of SGMT Stock?

Wall Street analysts forecast SGMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMT is27.00 USD with a low forecast of 8.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sagimet Biosciences Inc (SGMT)'s revenue for the last quarter?

Sagimet Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Sagimet Biosciences Inc (SGMT)'s earnings per share (EPS) for the last quarter?

Sagimet Biosciences Inc. EPS for the last quarter amounts to -0.40 USD, decreased -11.11

How many employees does Sagimet Biosciences Inc (SGMT). have?

Sagimet Biosciences Inc (SGMT) has 14 emplpoyees as of March 05 2026.

What is Sagimet Biosciences Inc (SGMT) market cap?

Today SGMT has the market capitalization of 187.32M USD.